Physician profile
Lexi Derry
NPI 1063709491
$788.56
in general payments reported to CMS, 2019-2025
11 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $130 · 2021: $38.97 · 2023: $106 · 2024: $94.92 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $211.23 | 2023-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $136.70 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $66.09 | 2024-2025 | Eylea Hd |
| Lensar, INC. | $59.66 | 2020 | |
| Optos, INC. | $55.65 | 2019 | |
| Bausch & Lomb Americas INC. | $54.36 | 2023-2024 | Vyzulta, Envista Mx60 Iol, Miebo |
| Alcon Vision LLC | $52.02 | 2019-2020 | |
| Johnson & Johnson Vision Care, INC. | $47.76 | 2019-2020 | |
| Abbvie INC. | $46.38 | 2023-2025 | Durysta |
| Horizon Therapeutics Plc | $39.18 | 2021-2023 | Tepezza |
| Allergan, INC. | $19.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lexi Derry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.